You are here

ovarian cancer

FDA grants IND clearance for ovarian cancer trial of Oncoinvent

Clinical Trials Arena

Wed, 11/1/23 - 10:12 am

Mendus shows early comparability data for its universal cancer vaccine

Clinical Trials Arena

Thu, 09/21/23 - 10:39 am

Novocure’s tumor-treating electric fields fall short in ovarian cancer trial

Clinical Trials Arena

Tue, 08/29/23 - 11:11 am

tumor treating fields

Cyteir finally calls it quits after months of cost cutting

Fierce Biotech

Mon, 07/3/23 - 10:41 am

Cyteir Therapeutics

AstraZeneca, Merck's Lynparza picks up new NICE recommendation

Fierce Pharma

Fri, 06/9/23 - 10:15 am

fallopian tube cancer

ASCO 2023: Precigen reports positive early data for CAR-T therapy

BioSpace

Tue, 06/6/23 - 11:12 am

AstraZeneca study points to new uses for targeted cancer drug Enhertu

BioPharma Dive

Mon, 06/5/23 - 11:32 am

cervical cancer

ASCO: AstraZeneca guns for wider ovarian cancer market with Imfinzi-Lynparza combo. Will the FDA buy the plan?

Fierce Pharma

Sun, 06/4/23 - 04:24 pm

ImmunoGen’s drug Elahere offers hope for ovarian cancer patients

Clinical Trials Arena

Wed, 05/17/23 - 10:50 pm

clinical trials

platinum-resistant ovarian cancer

ImmunoGen reports positive top-line data from ovarian cancer therapy trial

Clinical Trials Arena

Thu, 05/4/23 - 09:17 am

platinum-resistant ovarian cancer

Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival

Fierce Biotech

Wed, 04/12/23 - 11:39 am

Junshi Biosciences

PARP inhibitors

GSK told to pay higher royalties to AZ on Zejula sales

Pharmaphorum

Thu, 04/6/23 - 11:37 am

AstraZeneca's Lynparza-Imfinzi combo clears PhIII trial in ovarian cancer

Endpoints

Wed, 04/5/23 - 10:14 am

clinical trials

Amid bankruptcy, Clovis reveals more regulatory troubles for Rubraca

Fierce Pharma

Mon, 02/13/23 - 10:48 am

Clovis Oncology

Cyteir lays off 70% of workforce after further narrowing cancer drug goals

Fierce Biotech

Fri, 01/20/23 - 10:28 am

Cyteir Therapeutics

Sutro shells out latest update on ovarian cancer treatment, plans for pivotal trial

Endpoints

Tue, 01/10/23 - 10:54 am

Sutro BioPharma

clinical trials

antibody-drug conjugate

luveltamab tazevibulin

OncoC4 doses first participant in ovarian cancer therapy trial

Clinical Trials Arena

Mon, 01/2/23 - 06:33 pm

clinical trials

platinum-resistant ovarian cancer

Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial

Seeking Alpha

Tue, 12/6/22 - 10:31 am

Bristol Myers Squibb

platinum-resistant ovarian cancer

In free fall, Clovis defaults on loan and agrees to further restrict Rubraca use

Fierce Pharma

Mon, 12/5/22 - 11:07 am

Clovis Oncology

With the walls closing in for Clovis, FDA demands ovarian cancer restriction for Rubraca

Fierce Biotech

Thu, 11/17/22 - 10:52 am

Clovis Oncology

Pages